US20090245612A1 - Automated image analysis - Google Patents

Automated image analysis Download PDF

Info

Publication number
US20090245612A1
US20090245612A1 US12/480,452 US48045209A US2009245612A1 US 20090245612 A1 US20090245612 A1 US 20090245612A1 US 48045209 A US48045209 A US 48045209A US 2009245612 A1 US2009245612 A1 US 2009245612A1
Authority
US
United States
Prior art keywords
objects
imaging process
images
automated imaging
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/480,452
Inventor
David Zahniser
Kam Lin Wong
Jim Linder
Douglas Tenney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytyc Corp
Original Assignee
Cytyc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytyc Corp filed Critical Cytyc Corp
Priority to US12/480,452 priority Critical patent/US20090245612A1/en
Assigned to GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT reassignment GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT TWELFTH SUPPLEMENT TO PATENT SECURITY AGREEMENT Assignors: CYTYC CORPORATION
Publication of US20090245612A1 publication Critical patent/US20090245612A1/en
Assigned to CYTYC SURGICAL PRODUCTS III, INC., DIRECT RADIOGRAPHY CORP., HOLOGIC, INC., CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP, CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP, BIOLUCENT, LLC, SUROS SURGICAL SYSTEMS, INC., CYTYC PRENATAL PRODUCTS CORP., R2 TECHNOLOGY, INC., CYTYC CORPORATION, THIRD WAVE TECHNOLOGIES, INC. reassignment CYTYC SURGICAL PRODUCTS III, INC. TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Assignors: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429Signal processing
    • G01N15/1433Signal processing using image recognition
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00Pattern recognition
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00Image analysis
    • G06T7/0002Inspection of images, e.g. flaw detection
    • G06T7/0012Biomedical image inspection
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06VIMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00Scenes; Scene-specific elements
    • G06V20/60Type of objects
    • G06V20/69Microscopic objects, e.g. biological cells or cellular parts
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N2015/1006Investigating individual particles for cytology
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/20Special algorithmic details
    • G06T2207/20212Image combination
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00Indexing scheme for image analysis or image enhancement
    • G06T2207/30Subject of image; Context of image processing
    • G06T2207/30004Biomedical image processing
    • G06T2207/30024Cell structures in vitro; Tissue sections in vitro
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S128/00Surgery
    • Y10S128/92Computer assisted medical diagnostics
    • Y10S128/922Computer assisted medical diagnostics including image analysis

Definitions

  • the subject matter described herein relates to methods and devices useful in automated image analysis.
  • Automated cytological imagers have been developed to meet the need for more uniform cytological image analyses. Automated cytological imagers do not vary as greatly in their interpretations of slides, are less subject to fatigue, and can provide much greater throughput as compared to humans.
  • Automated screeners can be used to select from each sample, objects for further human review. This method can increase the sensitivity of such assays, as the machine may more readily and economically identify those objects of interest in each sample to be analyzed by a human.
  • the classification of abnormal objects in a conventional automated screening system can be complicated by the presence of normal metaplastic cells and other confounding objects.
  • Some imaging systems identify cells of interest in pap-stained specimens on the basis of their optical density, as they or their nuclei may appear “darker” (more optically dense) and/or larger than do normal cells in the specimen.
  • Metaplastic cells in the stained specimen also have dark cytoplasms and consequently reduced nuclear:cytoplasmic contrast that may contribute to errors in measurement.
  • the metaplastic cells can be quite numerous on a slide, while abnormal cells may appear infrequently, and thus automated imagers can undesirably select the metaplastic cells for human review as they appear equivalently dark to the imager but are much more numerous than the abnormal cells.
  • the false selection rate of the frequently occurring but disease-negative metaplastic cells by the imager thus limits accurate disease detection.
  • an automated imaging process includes: a) obtaining digital images of objects in a biological sample; b) selecting a plurality of objects of interest from the digital images; c) obtaining multiple images of the objects of interest at a plurality of different wavelengths; d) combining one of said multiple images with a corresponding digital image to produce a combined image; and e) analyzing the combined image in order to characterize the biological sample.
  • an automated imaging process includes: a) obtaining digital images of objects in a biological sample; b) selecting at least one object of interest from the digital images; c) obtaining at least one image of the at least one object of interest at a plurality of different wavelengths to form a set of multi-wavelength images; d) analyzing the set of multi-wavelength images in order to characterize the biological sample.
  • an apparatus for use in a automated imaging process includes: a) at least one light source that can provide at least one spectral region to a sample; b) at least one detector that can detect at least one set of images of portions of the sample when illuminated by the at least one spectral region; and c) at least one computer that can select at least one subset of the images based on at least one set of criteria. If more than two sets of the images are collected, those images may be combined to form at least one combined image. Then at least one computer may also analyze the sets of images for the selected subset and can select a further subset of the sets of images based on a second set of criteria which may be the first set of criteria or a different set.
  • an apparatus for use in an automated imaging process includes: a) a first light source that can provide a first spectral region to a sample; b) a first detector that can detect first images of portions of the sample when illuminated by the first spectral region; c) a first computer that can select a subset of the first images based a first set of criteria; d) a second light source, which may be the first light source or a different light source, that can provide a second spectral region different from the first spectral region; e) a second detector, which may be the first detector or a different detector, that can detect a second image of the images in the selected subset when illuminated by the second spectral region; and f) a second computer, which may be the first computer or a different computer, that can produce a combined image comprising the second image and the first image for the selected subset and can select a further subset of the combined images based on a second set of criteria which may be the
  • an apparatus for use in an automated imaging process includes: a) a first light source that can provide a first spectral region to a sample; b) a first detector that can detect first images of portions of the sample when illuminated by the first spectral region; c) a first computer that can select a subset of the first images based a first set of criteria; d) a second light source, which may be the first light source or a different light source, that can provide a second spectral region different from the first spectral region; e) a second detector, which may be the first detector or a different detector, that can detect a second image of the images in the selected subset when illuminated by the second spectral region; and f) a second computer, which may be the first computer or a different computer, that can analyze the first and second images for the selected subset and can select a further subset of the first and second images based on second set of criteria which may be the first set of criteria or
  • FIG. 1 depicts the incremental nuclear:cytoplasmic contrast levels for a dual wavelength (570 nm plus 2nd wavelength) combined image as compared to a single wavelength (570 nm) image, for 11 measured objects.
  • Circle normal intermediate cell
  • x normal metaplastic cell
  • dot abnormal cell.
  • Automated imaging processes and/or devices utilize multiple wavelengths of light to illuminate the sample and obtain images that can be manipulated automatically or by an operator, as described herein. Images that contain relevant information can also be obtained at different wavelengths in order to subject the combined image to additional analysis. In addition, objects found in one image can be subjected to different wavelengths of light in order to analyze the object in depth before rendering a diagnosis based on the sample. In some embodiments, relevant information can be obtained by illuminating the sample or specimen with white light and placing at least one color filter between the specimen/sample and at least one TV camera or other camera. A camera with switchable color filters may also be utilized. In some embodiments, an operator of the system may go back to the cell location, if a particular set of images comprises a “cell of interest”, and produce or retrieve additional images to aid the researcher, computer or technician in completing the information about the sample or specimen.
  • methods, processes and devices may be used singly or in combination.
  • cells or clusters containing features of interest (“positives”) can be better distinguished from false alarm or negative cells in a selected set.
  • Specific cell types such as endometrial cells or endocervical cells, or cells of a certain abnormality, may also be identified through such interrogation.
  • a number of discrete imaging systems are commercially available as of the time that the application for the present patent was filed, including Cytyc Corporation's THINPREP® Imaging System, the TriPath FOCALPOINTTM Profiler, the ChromaVision ACIS® System, the CompuCyt iCyte Imaging System, the Applied Imaging CYTOVISIONTM System, and the Veracel VerasysTM Imaging System. It will be appreciated that these apparatus and devices can be modified to incorporate additional imaging steps, such as those described herein.
  • the current THINPREP® Imaging System (“TIS”) identifies fields of view having one or more objects of interest in a specimen sample slide, including both single cells and clusters, stained by a Papanicolaou staining process and digitally imaged.
  • the TIS can compile a list, for example, of the 100 single objects on a given sample slide with the highest integrated optical density and a list of the 20 clusters with the highest average optical density. Other values of objects and clusters can be collected above or below the 100 and 20 values previously described. Additional analysis as provided herein improves discrimination, proper selection and improved analysis of these identified objects. This additional level of analysis is unique in that it is focused on identified objects and involves the use of spectral analysis.
  • Contemplated methods of identifying wavelength(s) of light allow for an improved categorization of a cytological sample involve scanning a sample throughout a spectral region and determining if particular wavelength(s) within that region allow for improved categorization of a sample parameter.
  • the sample may be scanned at regular or irregular intervals throughout the spectral region, and then combined in different ways with an unmodified image and/or with one or more different wavelength-specific images.
  • One portion of the sample may also be scanned at regular or irregular intervals throughout the spectral region with each wavelength-specific portion being reviewed automatically or by the user, thus creating multiple wavelength-specific images of the same portion of the sample.
  • sample parameters may be analyzed to determine their affect on the ability to more accurately categorize an imaged sample.
  • the regularity of the shape of the nucleus can provide important clues as to the status of the imaged cell and an irregularity in the nuclear shape can indicate a pre-malignant status. Therefore an improved ability to identify the nucleus, for example, by increasing contrast between the nucleus and cytoplasm, would yield an improved method of automatically diagnosing the condition of the cells.
  • imaging the nucleus of the cells includes determining the texture of the nucleus, its shape, the integrated darkness, the average darkness or a combination thereof.
  • Texture refers to analyzing the value of a given pixel in comparison with neighboring pixels, as known in the art.
  • Shape can be determined through any suitable technique, for example by determining the square of the perimeter divided by 4 ⁇ times area.
  • the “ring” of cytoplasm surrounding the nucleus may also be used. The optical density of the cytoplasm in this ring may be subtracted digitally from the image to provide for increased ability to measure the nucleus and can allow for improved visualization in situations where the cytoplasm of different cells overlap each other in a sample.
  • Contemplated staining methods include hematoxylin and eosin staining, Feulgen stain, DNA staining, stoichiometric staining, and counterstaining. In some embodiments, the methods may include or utilize samples which are not stained. Additionally, although the examples depict the use of the methods with regard to gynecological samples obtained from pap smears, any suitable biological sample may similarly be utilized in the methods described herein.
  • methods, process and/or apparatus described herein combine the ability of existing automated imaging systems, such as the TIS, with the additional capability to analyze an identified subset of “objects of interest” in a specimen sample in order to provide for the automatic recognition of normal cells, abnormal cells, particular disease-related conditions, or a combination thereof.
  • One automated imaging process comprises: a) obtaining digital images of objects in a biological sample; b) selecting a plurality of objects of interest from the digital images; c) obtaining multiple images of the objects of interest at a plurality of different wavelengths; d) combining one of said multiple images with a corresponding digital image to produce a combined image; and e) analyzing the combined image in order to characterize the biological sample.
  • objects of interest are identified in the sample, and then additional images of these objects are obtained by illuminating the objects with other spectral regions.
  • the additional images may be combined by any mathematical means, such as, e.g., additively, subtractively, and/or in a ratio in the combined image. More than two images may be combined.
  • the combined images are then analyzed by a set of criteria as described herein, and the results are compared to those obtained from single-wavelength illumination. In this manner, additional useful illumination wavelengths can be identified.
  • the additional images at a plurality of wavelengths may be acquired at the same time as the original image was acquired and then stored for later possible use. Or, objects may be relocated and new images at a plurality of wavelengths may then be acquired.
  • Another contemplated automated imaging process comprises: a) obtaining digital images of objects in a biological sample; b) selecting at least one object of interest from the digital images; c) obtaining at least one image of the at least one object of interest at a plurality of different wavelengths to form a set of multi-wavelength images; d) analyzing the set of multi-wavelength images in order to characterize the biological sample.
  • At least one image collected at a plurality of different wavelengths is used to extract features from the images. For example a ratio of darkness in the red end of the spectrum divided by darkness in the blue end of the spectrum would be useful in characterizing the image taken from the biological sample.
  • This contemplated embodiment is designed to provide multiple perspectives on the same image or collection of images from a biological sample.
  • the user might take 4 or 5 images and find that some weighted value of the pixels within the nuclei from the different images give a result that may indicate abnormality versus normalcy. This process would give a “spectral signature” of the images from the biological sample.
  • the imager first identifies the specific subset based on the highest integrated optical density nuclei and the highest average optical density clusters.
  • the subset typically includes abnormal objects and some “false alarms.”
  • the subset typically includes normal objects and also some “false alarms.” The false alarms are due to the presence of reactive/repair types of cells or artifacts such as overlapping nuclei or normal objects with inherently low contrast between the nucleus and the cytoplasm.
  • the imager returns to these identified objects and applies additional analysis or analyses to better sort true abnormal objects from reactive/repair type changes and/or from “false alarms.”
  • the additional analysis can include spectral analysis or marker detection, and can involve measurements taken from both the nucleus and cytoplasm of the cells.
  • a spectral analysis is performed on a specific subset of objects, such as the top 2000 objects, the top 1000 objects or less, such as the top 500 objects, the top 200 objects or the top 120 objects.
  • the number of objects chosen for the subset is a function of such things as the computer memory, computer speed and the need of the user to characterize the sample with increasing accuracy.
  • an analysis of the top 120 images or objects from that subset can be selected based on suitable criteria. So, for example, a subset of objects may contain 2000 images taken at one wavelength. At another wavelength, 1000 images are collected. During analysis, 120 images are pulled from each of the 2000 image set and the 1000 image set.
  • images at a plurality of wavelengths may be stored at the time the initial images are acquired. Then additional analyses may be performed on the subset of objects of interest without relocating the object.
  • Multiple wavelengths of light can be used to digitize black and white images taken at a single or multiple wavelengths.
  • the resulting “color” images may be more easily characterized than a single black and white image.
  • a classification of the objects can then be attempted. Based upon the analysis of the identified objects, a decision can made to identify a specimen as normal without requiring any additional review by a human.
  • Spectral information can also be used to identify specific types of cells. For example, in identifying a list of clusters it would be desirable to identify endometrial cells, or endocervical cells. In identifying a list of single nuclei, identification of metaplastic or endocervical cells or other specific cell types can be useful to the cytologist. In both types of identification, a certain level of abnormality can be determined through spectral analysis as provided herein. Such measurements can include nuclear and cytoplasmic measures of morphology and spectral information.
  • Spectral information can also detect certain cellular changes associated with disease or other cellular changes.
  • HPV infection may cause a cellular change that results in a spectral change. This can be detected by an imager, allowing the sample to be identified as being infected with HPV, without requiring a molecular assay.
  • markers Changes in cells due to the presence of disease or infection are often demonstrated by the presence of markers.
  • antibodies can detect the presence of an infection, for example an HPV or Chlamydia infection.
  • Other molecular markers such as nucleic acid probes or aptamers, can also be used to indicate the presence of disease or infection.
  • probes can be attached to a unique color label that is not normally present in the stain being used, for example a standard Pap stain. This label can comprise a certain absorption spectrum, or it may fluoresce only when a certain wavelength of light is used for illumination. The color analysis and/or illumination of the marker can be done on the identified objects.
  • this approach provides subsequent analysis of a reduced number of objects on the slide, which allows faster execution than can be obtained with a full slide analysis. It also allows for increased sensitivity or specificity since the additional analysis is only applied to objects that are already selected as suspicious due to perceived changes in a relevant property, for example nuclear density.
  • the TIS for example, identifies the 100 objects (usually nuclei) with the highest integrated optical density (IOD).
  • IOD integrated optical density
  • a spectral analysis can be made of some or all of those 100 identified objects. The spectral analysis can be used to give an indication of whether these are cell nuclei having spectral characteristics more similar to negative cell nuclei or to abnormal cell nuclei. Based upon this analysis a decision can be made that the slide is likely negative and no further human analysis may be required.
  • automated spectral imaging methods include automated analysis of specimens for diagnosis, sorting, or selecting cells for additional analysis, for Pap tests, ductal lavage, lung, etc.; and improved segmentation analysis by combinations of images obtained from two or more colors of illumination. Also, automated methods may include steps involving multispectral unmixing, segmentation, and/or quantification of the images or objects of interest.
  • LED Light emitting diode
  • the sample which also may be referred to as the specimen, that is analyzed can be any source of biological material that can be obtained from an organism directly or indirectly, including cells, tissue or fluid.
  • the sample include blood, urine, semen, milk, sputum, mucus, plueral fluid, pelvic fluid, synovial fluid, ascites fluid, body cavity washes, eye brushing, skin scrapings, a buccal swab, a vaginal swab, a pap smear, a rectal swab, an aspirate, a needle biopsy, a section of tissue obtained for example by surgery or autopsy, plasma, serum, spinal fluid, lymph fluid, the external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, tumors, organs, a microbial culture, a virus, and samples of in vitro cell culture constituents.
  • the sample can be a positive control sample which is known to contain an object of interest.
  • the object of interest that may be selected by the automated device may be any component of the sample that is desired to be detected.
  • Non-limiting examples of the object include a polynucleotide, a protein, a peptide, a polysaccharide, mucopolysaccharide, proteoglycan, a carbohydrate, a lipid, a fat, a cell, a cell type, an organism, a virus, a structure, an antigen, an inorganic compound, or other molecule to which a sensor can be obtained.
  • Exemplary molecular objects include HPV E2 protein, HPV E6 and E7 proteins, HPV L1 capsid protein, p16INK4a, E-cadherin, N-cadherin, p53, GCDFP-15, Pericyclin, NuMA, carbonic anhydrase, matrix metalloproteinases, nuclear matrix proteins, ferritin, aurora A, pericentrin, osteopontin, prostatin, insulin-like growth factor, fibroblast growth factor, BRCA1, BRCA2, mammoglobin, PSE, CEA, CA-125, CA 19-9, CA 15-3, somatostatin, synaptophysin, chromogranin, kallikriens, fibronectin, EGFR, K-ras, Her-2/neu, treponemal antigen, neuron-specific enolase, retinoblastoma protein, hepatitis C surface antigen, sexually transmitted disease markers including the outer membrane protein of Chlamydia
  • the cell can be of any origin, including prokaryotic, eukaryotic, or archea.
  • the cell may be living or dead. If obtained from a multicellular organism, the cell may be of any cell type.
  • the cell may be a cultured cell line or a primary isolate, the cell may be mammalian, amphibian, reptilian, plant, yeast, bacterial, mycobacterial, spirochetal, or protozoan.
  • the cell may be human, murine, rat, hamster, chicken, quail, or dog.
  • the cell may be a normal cell, a mutated cell, a genetically manipulated cell, a tumor cell, etc.
  • a device in one embodiment for performing the automated imaging methods described herein, includes one or more light sources capable of illuminating the specimen at multiple wavelengths of light.
  • the device also includes one or more detectors capable of obtaining images of the specimen at multiple wavelengths of illumination.
  • the device also includes a computer or other selection means capable of selecting a subset of objects of interest from images obtained from the specimen at a first wavelength.
  • the device may select these objects based on any set of criteria, which may include one or multiple separate analyses. Examples of such criteria are provided herein, including average optical density, integrated optical density, shape, texture, etc.
  • the device is capable of imaging the identified objects of interest at a second wavelength, and then combining these additional images with the first image of the objects to produce a combined image, which can then be subject to additional analyses to select a particular subset of the objects based on further criteria, which may be the same or different criteria as performed initially.
  • Images can be added together or compared to one another by analog devices or by digital devices. For example, two images may be added together by turning on two colors of illumination simultaneously (i.e. from two different wavelength LED's) and adding the images in an analog process. In other embodiments, the images may be digitized and added or compared.
  • a set of eleven microscope fields containing normal, abnormal and metaplastic Papanicolaou-stained cells was digitized using 51 different wavelengths using a Zeiss Axioskop microscope with a black and white video camera. This was accomplished by placing a monochrometer (EG&G model 585-22) between the light source and the microscope. Images were then digitized at wavelengths between 450 and 700 nanometers, in steps of 5 nanometers. Once the multiple wavelength images were digitized, an algorithm was explored to add combinations of two images together, and then automatically determine contrast between cell nuclei and cytoplasms. Contrast was defined as the grey level difference of a 10 ⁇ 10 pixel box within the nucleus compared to a 10 ⁇ 10 pixel box within the cytoplasm. A single wavelength, 570 nm, was chosen that gave optimal contrast for most images.
  • a range (between approximately 600 and 670) was identified where contrast was improved in the combined image for all objects, regardless of cytoplasmic color or cell type. This demonstrates that contrast can be improved combining images from multiple wavelengths.
  • a series of abnormal cells and normal metaplastic cells from Pap stained slides were digitized using a Zeiss Axioskop microscope with a black and white video camera using two wavelengths, 570 and 650 nm, selected based on Example 1.
  • Full images were digitized to allow “confusion” of clusters, debris, blood, etc.
  • the images were first analyzed using only a single wavelength—the standard green illumination used in many Pap test imaging systems (570 nm). The images were then analyzed using a combination of the two wavelengths 570 and 650 nm.
  • the segmentation algorithm works by automatically finding potential nuclei (dark objects), and then uses an iterative method based upon the grey level histogram of the image. This method monitors changes in the minimum and maximum darkness values from a histogram of the grey levels within the current outline of the object.
  • Many other segmentation methods can be applied to locate nuclei, cytoplasms or other objects in an image.
  • features of the nuclei are extracted and a rejection of artifacts is done, based upon shape and texture measurements.
  • IOD integrated optical density
  • the images were analyzed for clusters by comparing data from matching clusters in the single wavelength and dual wavelength combined images.
  • the data showed a significant improvement in the difference in standard deviation of grey levels between the “salt and pepper” appearance of white blood cell clusters and the smoother clusters (less variation in pixel density) of abnormal cells. This feature is important as it allows removal of “false alarms” due to white blood cell clusters. Without this discrimination, an imager may select some of the very numerous white blood cell clusters to show a cytotechnologist instead of the less frequent abnormal clusters that might be on the same slide. These data clearly indicate that contrast was improved, permitting better discrimination by the imager. Dual wavelength illumination allowed improved segmentation and classification in a clinical application with cells from Pap test slides.

Landscapes

  • Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Signal Processing (AREA)
  • Multimedia (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Quality & Reliability (AREA)
  • Evolutionary Biology (AREA)
  • Evolutionary Computation (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Artificial Intelligence (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Image Processing (AREA)

Abstract

One automated imaging process, as described herein, includes: a) obtaining digital images of objects in a biological sample; b) selecting a plurality of objects of interest from the digital images; c) obtaining multiple images of the selected objects of interest at a plurality of different wavelengths; d) combining one of said multiple images with a corresponding digital image to produce a combined image; and e) analyzing the combined image in order to characterize the biological sample.

Description

    RELATED APPLICATION DATA
  • The present application is a continuation of pending U.S. patent application Ser. No. 11/120,437, filed May 2, 2005, the priority of which is claimed under 35 U.S.C. §120, and the contents of which is incorporated herein by reference in its entirety, as though set forth in full.
  • FIELD OF THE SUBJECT MATTER
  • The subject matter described herein relates to methods and devices useful in automated image analysis.
  • BACKGROUND
  • Cytological imaging of medical specimens is a tedious but crucial tool for medical analyses. Automated cytological imagers have been developed to meet the need for more uniform cytological image analyses. Automated cytological imagers do not vary as greatly in their interpretations of slides, are less subject to fatigue, and can provide much greater throughput as compared to humans.
  • Several previously developed and some currently available automated systems are used in conjunction with additional human analysis, and are used to increase the number of samples assayed and to lessen the fatigue experienced by the human analyst. Automated screeners can be used to select from each sample, objects for further human review. This method can increase the sensitivity of such assays, as the machine may more readily and economically identify those objects of interest in each sample to be analyzed by a human.
  • However, automated imagers are limited by the sample and data provided to them and by their programming. Additionally, for computational reasons, imagers typically use monochromatic, black and white images for their analyses, whereas the sample itself may provide a great range of spectral data and other information, particularly for cytologically stained samples.
  • For example, in the automated image analysis of pap-stained samples, the classification of abnormal objects in a conventional automated screening system can be complicated by the presence of normal metaplastic cells and other confounding objects. Some imaging systems identify cells of interest in pap-stained specimens on the basis of their optical density, as they or their nuclei may appear “darker” (more optically dense) and/or larger than do normal cells in the specimen. Metaplastic cells in the stained specimen also have dark cytoplasms and consequently reduced nuclear:cytoplasmic contrast that may contribute to errors in measurement. The metaplastic cells can be quite numerous on a slide, while abnormal cells may appear infrequently, and thus automated imagers can undesirably select the metaplastic cells for human review as they appear equivalently dark to the imager but are much more numerous than the abnormal cells. The false selection rate of the frequently occurring but disease-negative metaplastic cells by the imager thus limits accurate disease detection.
  • SUMMARY OF THE SUBJECT MATTER
  • In accordance with one embodiment disclosed herein, an automated imaging process includes: a) obtaining digital images of objects in a biological sample; b) selecting a plurality of objects of interest from the digital images; c) obtaining multiple images of the objects of interest at a plurality of different wavelengths; d) combining one of said multiple images with a corresponding digital image to produce a combined image; and e) analyzing the combined image in order to characterize the biological sample.
  • In accordance with another embodiment disclosed herein, an automated imaging process includes: a) obtaining digital images of objects in a biological sample; b) selecting at least one object of interest from the digital images; c) obtaining at least one image of the at least one object of interest at a plurality of different wavelengths to form a set of multi-wavelength images; d) analyzing the set of multi-wavelength images in order to characterize the biological sample.
  • In accordance with yet another embodiment disclosed herein, an apparatus for use in a automated imaging process includes: a) at least one light source that can provide at least one spectral region to a sample; b) at least one detector that can detect at least one set of images of portions of the sample when illuminated by the at least one spectral region; and c) at least one computer that can select at least one subset of the images based on at least one set of criteria. If more than two sets of the images are collected, those images may be combined to form at least one combined image. Then at least one computer may also analyze the sets of images for the selected subset and can select a further subset of the sets of images based on a second set of criteria which may be the first set of criteria or a different set.
  • In accordance with still another embodiment disclosed herein, an apparatus for use in an automated imaging process includes: a) a first light source that can provide a first spectral region to a sample; b) a first detector that can detect first images of portions of the sample when illuminated by the first spectral region; c) a first computer that can select a subset of the first images based a first set of criteria; d) a second light source, which may be the first light source or a different light source, that can provide a second spectral region different from the first spectral region; e) a second detector, which may be the first detector or a different detector, that can detect a second image of the images in the selected subset when illuminated by the second spectral region; and f) a second computer, which may be the first computer or a different computer, that can produce a combined image comprising the second image and the first image for the selected subset and can select a further subset of the combined images based on a second set of criteria which may be the first set of criteria or a different set.
  • In accordance with a still further embodiment disclosed herein, an apparatus for use in an automated imaging process includes: a) a first light source that can provide a first spectral region to a sample; b) a first detector that can detect first images of portions of the sample when illuminated by the first spectral region; c) a first computer that can select a subset of the first images based a first set of criteria; d) a second light source, which may be the first light source or a different light source, that can provide a second spectral region different from the first spectral region; e) a second detector, which may be the first detector or a different detector, that can detect a second image of the images in the selected subset when illuminated by the second spectral region; and f) a second computer, which may be the first computer or a different computer, that can analyze the first and second images for the selected subset and can select a further subset of the first and second images based on second set of criteria which may be the first set of criteria or a different set.
  • BRIEF DESCRIPTION OF THE FIGURE
  • FIG. 1 depicts the incremental nuclear:cytoplasmic contrast levels for a dual wavelength (570 nm plus 2nd wavelength) combined image as compared to a single wavelength (570 nm) image, for 11 measured objects. Circle=normal intermediate cell, x=normal metaplastic cell, dot=abnormal cell.
  • DETAILED DESCRIPTION
  • Automated imaging processes and/or devices utilize multiple wavelengths of light to illuminate the sample and obtain images that can be manipulated automatically or by an operator, as described herein. Images that contain relevant information can also be obtained at different wavelengths in order to subject the combined image to additional analysis. In addition, objects found in one image can be subjected to different wavelengths of light in order to analyze the object in depth before rendering a diagnosis based on the sample. In some embodiments, relevant information can be obtained by illuminating the sample or specimen with white light and placing at least one color filter between the specimen/sample and at least one TV camera or other camera. A camera with switchable color filters may also be utilized. In some embodiments, an operator of the system may go back to the cell location, if a particular set of images comprises a “cell of interest”, and produce or retrieve additional images to aid the researcher, computer or technician in completing the information about the sample or specimen.
  • Also provided herein are several methods, processes and devices of and for further investigating a set of objects by an automated imager, which methods, processes and devices may be used singly or in combination. Through the use of information obtained by analyzing objects at multiple wavelengths, cells or clusters containing features of interest (“positives”) can be better distinguished from false alarm or negative cells in a selected set. Specific cell types, such as endometrial cells or endocervical cells, or cells of a certain abnormality, may also be identified through such interrogation.
  • A number of discrete imaging systems are commercially available as of the time that the application for the present patent was filed, including Cytyc Corporation's THINPREP® Imaging System, the TriPath FOCALPOINT™ Profiler, the ChromaVision ACIS® System, the CompuCyt iCyte Imaging System, the Applied Imaging CYTOVISION™ System, and the Veracel Verasys™ Imaging System. It will be appreciated that these apparatus and devices can be modified to incorporate additional imaging steps, such as those described herein.
  • The current THINPREP® Imaging System (“TIS”) identifies fields of view having one or more objects of interest in a specimen sample slide, including both single cells and clusters, stained by a Papanicolaou staining process and digitally imaged. The TIS can compile a list, for example, of the 100 single objects on a given sample slide with the highest integrated optical density and a list of the 20 clusters with the highest average optical density. Other values of objects and clusters can be collected above or below the 100 and 20 values previously described. Additional analysis as provided herein improves discrimination, proper selection and improved analysis of these identified objects. This additional level of analysis is unique in that it is focused on identified objects and involves the use of spectral analysis.
  • Contemplated methods of identifying wavelength(s) of light allow for an improved categorization of a cytological sample involve scanning a sample throughout a spectral region and determining if particular wavelength(s) within that region allow for improved categorization of a sample parameter. The sample may be scanned at regular or irregular intervals throughout the spectral region, and then combined in different ways with an unmodified image and/or with one or more different wavelength-specific images. One portion of the sample may also be scanned at regular or irregular intervals throughout the spectral region with each wavelength-specific portion being reviewed automatically or by the user, thus creating multiple wavelength-specific images of the same portion of the sample.
  • A variety of different sample parameters may be analyzed to determine their affect on the ability to more accurately categorize an imaged sample. In some embodiments, it may be desirable to identify the border of the nucleus. The regularity of the shape of the nucleus can provide important clues as to the status of the imaged cell and an irregularity in the nuclear shape can indicate a pre-malignant status. Therefore an improved ability to identify the nucleus, for example, by increasing contrast between the nucleus and cytoplasm, would yield an improved method of automatically diagnosing the condition of the cells.
  • In some embodiments, imaging the nucleus of the cells includes determining the texture of the nucleus, its shape, the integrated darkness, the average darkness or a combination thereof. Texture refers to analyzing the value of a given pixel in comparison with neighboring pixels, as known in the art. Shape can be determined through any suitable technique, for example by determining the square of the perimeter divided by 4π times area. Additionally, the “ring” of cytoplasm surrounding the nucleus may also be used. The optical density of the cytoplasm in this ring may be subtracted digitally from the image to provide for increased ability to measure the nucleus and can allow for improved visualization in situations where the cytoplasm of different cells overlap each other in a sample.
  • Although the examples herein describe cytological samples stained by a Papanicolaou staining process, it should be understood that the methods described herein can be used in conjunction with samples stained by other suitable and/or conventional processes and/or materials. Contemplated staining methods include hematoxylin and eosin staining, Feulgen stain, DNA staining, stoichiometric staining, and counterstaining. In some embodiments, the methods may include or utilize samples which are not stained. Additionally, although the examples depict the use of the methods with regard to gynecological samples obtained from pap smears, any suitable biological sample may similarly be utilized in the methods described herein.
  • Where a combination is disclosed herein, it is to be understood that each sub-combination of the elements of that combination is also specifically disclosed and is within the scope of the subject matter. Conversely, where different elements or groups of elements are disclosed, combinations thereof are also disclosed. Where any element of the subject matter is disclosed as having a plurality of alternatives, examples of that subject matter in which each alternative is excluded singly or in any combination with the other alternatives are also hereby disclosed; more than one element of contemplated subject matter can have such exclusions, and all combinations of elements having such exclusions are hereby disclosed.
  • Unless defined otherwise or the context clearly dictates otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the subject matter disclosed herein, the preferred methods and materials are now described.
  • As mentioned earlier, methods, process and/or apparatus described herein combine the ability of existing automated imaging systems, such as the TIS, with the additional capability to analyze an identified subset of “objects of interest” in a specimen sample in order to provide for the automatic recognition of normal cells, abnormal cells, particular disease-related conditions, or a combination thereof.
  • One automated imaging process, as described herein, comprises: a) obtaining digital images of objects in a biological sample; b) selecting a plurality of objects of interest from the digital images; c) obtaining multiple images of the objects of interest at a plurality of different wavelengths; d) combining one of said multiple images with a corresponding digital image to produce a combined image; and e) analyzing the combined image in order to characterize the biological sample.
  • In this contemplated embodiment, objects of interest are identified in the sample, and then additional images of these objects are obtained by illuminating the objects with other spectral regions. The additional images may be combined by any mathematical means, such as, e.g., additively, subtractively, and/or in a ratio in the combined image. More than two images may be combined. The combined images are then analyzed by a set of criteria as described herein, and the results are compared to those obtained from single-wavelength illumination. In this manner, additional useful illumination wavelengths can be identified. The additional images at a plurality of wavelengths may be acquired at the same time as the original image was acquired and then stored for later possible use. Or, objects may be relocated and new images at a plurality of wavelengths may then be acquired.
  • Another contemplated automated imaging process, as described herein, comprises: a) obtaining digital images of objects in a biological sample; b) selecting at least one object of interest from the digital images; c) obtaining at least one image of the at least one object of interest at a plurality of different wavelengths to form a set of multi-wavelength images; d) analyzing the set of multi-wavelength images in order to characterize the biological sample.
  • In this additional contemplated embodiment, at least one image collected at a plurality of different wavelengths is used to extract features from the images. For example a ratio of darkness in the red end of the spectrum divided by darkness in the blue end of the spectrum would be useful in characterizing the image taken from the biological sample. This contemplated embodiment is designed to provide multiple perspectives on the same image or collection of images from a biological sample. In related embodiments, the user might take 4 or 5 images and find that some weighted value of the pixels within the nuclei from the different images give a result that may indicate abnormality versus normalcy. This process would give a “spectral signature” of the images from the biological sample.
  • In some embodiments, the imager first identifies the specific subset based on the highest integrated optical density nuclei and the highest average optical density clusters. In an abnormal specimen the subset typically includes abnormal objects and some “false alarms.” In a normal specimen the subset typically includes normal objects and also some “false alarms.” The false alarms are due to the presence of reactive/repair types of cells or artifacts such as overlapping nuclei or normal objects with inherently low contrast between the nucleus and the cytoplasm.
  • In some embodiments provided herein, the imager returns to these identified objects and applies additional analysis or analyses to better sort true abnormal objects from reactive/repair type changes and/or from “false alarms.” The additional analysis can include spectral analysis or marker detection, and can involve measurements taken from both the nucleus and cytoplasm of the cells.
  • In some embodiments disclosed herein, a spectral analysis is performed on a specific subset of objects, such as the top 2000 objects, the top 1000 objects or less, such as the top 500 objects, the top 200 objects or the top 120 objects. The number of objects chosen for the subset is a function of such things as the computer memory, computer speed and the need of the user to characterize the sample with increasing accuracy. Once the subset of objects is selected and stored, an analysis of the top 120 images or objects from that subset can be selected based on suitable criteria. So, for example, a subset of objects may contain 2000 images taken at one wavelength. At another wavelength, 1000 images are collected. During analysis, 120 images are pulled from each of the 2000 image set and the 1000 image set.
  • In other embodiments, rather than returning to the subset of objects, images at a plurality of wavelengths may be stored at the time the initial images are acquired. Then additional analyses may be performed on the subset of objects of interest without relocating the object.
  • Multiple wavelengths of light can be used to digitize black and white images taken at a single or multiple wavelengths. The resulting “color” images may be more easily characterized than a single black and white image. In some embodiments, a classification of the objects can then be attempted. Based upon the analysis of the identified objects, a decision can made to identify a specimen as normal without requiring any additional review by a human.
  • Spectral information can also be used to identify specific types of cells. For example, in identifying a list of clusters it would be desirable to identify endometrial cells, or endocervical cells. In identifying a list of single nuclei, identification of metaplastic or endocervical cells or other specific cell types can be useful to the cytologist. In both types of identification, a certain level of abnormality can be determined through spectral analysis as provided herein. Such measurements can include nuclear and cytoplasmic measures of morphology and spectral information.
  • Spectral information can also detect certain cellular changes associated with disease or other cellular changes. For example, HPV infection may cause a cellular change that results in a spectral change. This can be detected by an imager, allowing the sample to be identified as being infected with HPV, without requiring a molecular assay.
  • Changes in cells due to the presence of disease or infection are often demonstrated by the presence of markers. For example, antibodies can detect the presence of an infection, for example an HPV or Chlamydia infection. Other molecular markers, such as nucleic acid probes or aptamers, can also be used to indicate the presence of disease or infection. In some embodiments, probes can be attached to a unique color label that is not normally present in the stain being used, for example a standard Pap stain. This label can comprise a certain absorption spectrum, or it may fluoresce only when a certain wavelength of light is used for illumination. The color analysis and/or illumination of the marker can be done on the identified objects.
  • Overall, this approach provides subsequent analysis of a reduced number of objects on the slide, which allows faster execution than can be obtained with a full slide analysis. It also allows for increased sensitivity or specificity since the additional analysis is only applied to objects that are already selected as suspicious due to perceived changes in a relevant property, for example nuclear density.
  • The TIS, for example, identifies the 100 objects (usually nuclei) with the highest integrated optical density (IOD). In a system utilizing a method provided herein, a spectral analysis can be made of some or all of those 100 identified objects. The spectral analysis can be used to give an indication of whether these are cell nuclei having spectral characteristics more similar to negative cell nuclei or to abnormal cell nuclei. Based upon this analysis a decision can be made that the slide is likely negative and no further human analysis may be required.
  • Other embodiments of automated spectral imaging methods include automated analysis of specimens for diagnosis, sorting, or selecting cells for additional analysis, for Pap tests, ductal lavage, lung, etc.; and improved segmentation analysis by combinations of images obtained from two or more colors of illumination. Also, automated methods may include steps involving multispectral unmixing, segmentation, and/or quantification of the images or objects of interest.
  • It is to be understood that terms such as “color(s),” “wavelength(s)” and “spectral region(s)” used herein can encompass both precise wavelengths with narrow bandwidths, for example as might be provided by a laser source, and somewhat broader bandwidths as may be provided, for example, by the use of filters with a broad- or multi-band light source. Light emitting diode (LED) illumination can provide either narrow or somewhat broader illumination, depending on the individual LED.
  • The sample, which also may be referred to as the specimen, that is analyzed can be any source of biological material that can be obtained from an organism directly or indirectly, including cells, tissue or fluid. Nonlimiting examples of the sample include blood, urine, semen, milk, sputum, mucus, plueral fluid, pelvic fluid, synovial fluid, ascites fluid, body cavity washes, eye brushing, skin scrapings, a buccal swab, a vaginal swab, a pap smear, a rectal swab, an aspirate, a needle biopsy, a section of tissue obtained for example by surgery or autopsy, plasma, serum, spinal fluid, lymph fluid, the external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, tumors, organs, a microbial culture, a virus, and samples of in vitro cell culture constituents. The sample can be a positive control sample which is known to contain an object of interest.
  • The object of interest that may be selected by the automated device may be any component of the sample that is desired to be detected. Non-limiting examples of the object include a polynucleotide, a protein, a peptide, a polysaccharide, mucopolysaccharide, proteoglycan, a carbohydrate, a lipid, a fat, a cell, a cell type, an organism, a virus, a structure, an antigen, an inorganic compound, or other molecule to which a sensor can be obtained.
  • Exemplary molecular objects include HPV E2 protein, HPV E6 and E7 proteins, HPV L1 capsid protein, p16INK4a, E-cadherin, N-cadherin, p53, GCDFP-15, Pericyclin, NuMA, carbonic anhydrase, matrix metalloproteinases, nuclear matrix proteins, ferritin, aurora A, pericentrin, osteopontin, prostatin, insulin-like growth factor, fibroblast growth factor, BRCA1, BRCA2, mammoglobin, PSE, CEA, CA-125, CA 19-9, CA 15-3, somatostatin, synaptophysin, chromogranin, kallikriens, fibronectin, EGFR, K-ras, Her-2/neu, treponemal antigen, neuron-specific enolase, retinoblastoma protein, hepatitis C surface antigen, sexually transmitted disease markers including the outer membrane protein of Chlamydia trachomatis, cancer markers, and HIV gp120.
  • Where the object is a cell or cell component or product, the cell can be of any origin, including prokaryotic, eukaryotic, or archea. The cell may be living or dead. If obtained from a multicellular organism, the cell may be of any cell type. The cell may be a cultured cell line or a primary isolate, the cell may be mammalian, amphibian, reptilian, plant, yeast, bacterial, mycobacterial, spirochetal, or protozoan. The cell may be human, murine, rat, hamster, chicken, quail, or dog. The cell may be a normal cell, a mutated cell, a genetically manipulated cell, a tumor cell, etc.
  • In one embodiment for performing the automated imaging methods described herein, a device includes one or more light sources capable of illuminating the specimen at multiple wavelengths of light. The device also includes one or more detectors capable of obtaining images of the specimen at multiple wavelengths of illumination.
  • The device also includes a computer or other selection means capable of selecting a subset of objects of interest from images obtained from the specimen at a first wavelength. The device may select these objects based on any set of criteria, which may include one or multiple separate analyses. Examples of such criteria are provided herein, including average optical density, integrated optical density, shape, texture, etc. The device is capable of imaging the identified objects of interest at a second wavelength, and then combining these additional images with the first image of the objects to produce a combined image, which can then be subject to additional analyses to select a particular subset of the objects based on further criteria, which may be the same or different criteria as performed initially.
  • Images can be added together or compared to one another by analog devices or by digital devices. For example, two images may be added together by turning on two colors of illumination simultaneously (i.e. from two different wavelength LED's) and adding the images in an analog process. In other embodiments, the images may be digitized and added or compared.
  • EXAMPLES
  • The following examples are set forth so as to provide those of ordinary skill in the art with a complete description of how to make and use the subject matter described herein, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental error and deviation should be accounted for.
  • Example 1 Screening for Multiple Wavelengths to Improve Automated Imaging
  • An experiment was performed to determine if imaging a sample at multiple wavelengths could enhance the operation of the scene segmentation and/or feature extraction operations on an automated imager. Some abnormal cells and many metaplastic cells have reduced nuclear contrast due to very thick cytoplasms. Additionally, some staining systems produce multiple colors in a stained sample, and a single color of illumination may not be optimal for all cells in the sample. For example, Papanicolaou staining can produce cells with red, blue or green cytoplasms, and a single wavelength as used with some digital imagers may not provide optimum imaging of such divergent cells. Therefore, overall improvement in contrast was used as one means to assess potential methods for improving analysis.
  • A set of eleven microscope fields containing normal, abnormal and metaplastic Papanicolaou-stained cells was digitized using 51 different wavelengths using a Zeiss Axioskop microscope with a black and white video camera. This was accomplished by placing a monochrometer (EG&G model 585-22) between the light source and the microscope. Images were then digitized at wavelengths between 450 and 700 nanometers, in steps of 5 nanometers. Once the multiple wavelength images were digitized, an algorithm was explored to add combinations of two images together, and then automatically determine contrast between cell nuclei and cytoplasms. Contrast was defined as the grey level difference of a 10×10 pixel box within the nucleus compared to a 10×10 pixel box within the cytoplasm. A single wavelength, 570 nm, was chosen that gave optimal contrast for most images.
  • Combinations of this image with the other wavelengths were analyzed to determine the change in contrast from the 570 nm image, for a combined image (the two images were added together and then divided by 2). FIG. 1 shows a scatterplot of the net change in contrast (diff3 on the x axis; diff3=the difference in grey values between nucleus and cytoplasm for the dual wavelength image, minus the difference in grey values between the nucleus and cytoplasm for the single wavelength image) for each of eleven objects for all 51 wavelength combinations (y axis) with the 570 nm image.
  • A range (between approximately 600 and 670) was identified where contrast was improved in the combined image for all objects, regardless of cytoplasmic color or cell type. This demonstrates that contrast can be improved combining images from multiple wavelengths.
  • Example 2 Multiple Wavelength Imaging Improves Analysis of Difficult Specimens
  • In order to explore the potential of using multiple wavelength imaging, a series of abnormal cells and normal metaplastic cells from Pap stained slides were digitized using a Zeiss Axioskop microscope with a black and white video camera using two wavelengths, 570 and 650 nm, selected based on Example 1. Full images were digitized to allow “confusion” of clusters, debris, blood, etc. The images were first analyzed using only a single wavelength—the standard green illumination used in many Pap test imaging systems (570 nm). The images were then analyzed using a combination of the two wavelengths 570 and 650 nm.
  • Cells were then automatically segmented to find the nuclei. The segmentation algorithm works by automatically finding potential nuclei (dark objects), and then uses an iterative method based upon the grey level histogram of the image. This method monitors changes in the minimum and maximum darkness values from a histogram of the grey levels within the current outline of the object. Many other segmentation methods can be applied to locate nuclei, cytoplasms or other objects in an image. After segmentation, features of the nuclei are extracted and a rejection of artifacts is done, based upon shape and texture measurements. In order to test the performance of the combined image, a simple listing of cells in order using the integrated optical density (“IOD”) of the cells. This feature is one of the more discriminatory of all features measured on slides. However, difficulty has been encountered with “large/dark” but normal “metaplastic” cells appearing in positions in the list among the abnormal cells.
  • Patient samples with “troublesome” metaplastic cells were run and the 40 cells with the highest IOD were stored in a list. When only a single wavelength was used, metaplastic nuclei were appeared in the list among a set of abnormal nuclei characteristic of high grade squamous intraepithelial lesions, one at position 28 and more in positions 33 through 40. Many abnormal nuclei were found in the list of 100 nuclei with the highest integrated optical density.
  • When combined images from the two wavelengths were used to create the list of cellular IOD values from the same patient samples, however, of the first 40 nuclei the one and only metaplastic nucleus appeared in position 37. Now, more abnormal nuclei were shown in the first 40 position in the list. Thus, the combination demonstrated an ability to rank cells by providing fewer “false positive” nuclei in the top ranking and shows the usefulness of two color analysis with this very difficult problem.
  • As a final check, the images were analyzed for clusters by comparing data from matching clusters in the single wavelength and dual wavelength combined images. The data showed a significant improvement in the difference in standard deviation of grey levels between the “salt and pepper” appearance of white blood cell clusters and the smoother clusters (less variation in pixel density) of abnormal cells. This feature is important as it allows removal of “false alarms” due to white blood cell clusters. Without this discrimination, an imager may select some of the very numerous white blood cell clusters to show a cytotechnologist instead of the less frequent abnormal clusters that might be on the same slide. These data clearly indicate that contrast was improved, permitting better discrimination by the imager. Dual wavelength illumination allowed improved segmentation and classification in a clinical application with cells from Pap test slides.
  • Thus, specific embodiments, methods of use and applications of an improved automated image analysis system have been disclosed. It should be apparent, however, to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein.

Claims (22)

1. An automated imaging process, comprising:
obtaining digital images of objects in a biological sample;
selecting a plurality of objects of interest from the digital images;
obtaining multiple images of the selected objects of interest at a plurality of different wavelengths;
combining two or more of said multiple images to produce a combined image of the selected objects; and
analyzing the combined image in order to characterize the selected objects.
2. The automated imaging process of claim 1, wherein the objects of interest comprise objects of relatively high optical density compared with other objects in the biological sample.
3. The automated imaging process of claim 1, wherein the digital images are obtained from at least one wavelength in the range from ultraviolet to infrared.
4. The automated imaging process of claim 3, wherein the digital images are obtained from at least one wavelength of less than about 670 nm.
5. The automated imaging process of claim 1, wherein the plurality of different wavelengths are at uniform increments.
6. The automated imaging process of claim 1, wherein the objects of interest comprise cells.
7. The automated imaging process of claim 1, wherein the process is used to determine a normal specimen.
8. The automated imaging process of claim 1, wherein the process is used to identify an infection or other disease.
9. The automated imaging process of claim 1, wherein the characterization of the selected objects includes detection of a marker.
10. The automated imaging process of claim 1, wherein the characterization of the selected objects comprises detection of a spectral signature of an abnormal or infected cell.
11. An automated imaging process, comprising:
obtaining digital images of objects in a biological sample;
selecting at least one object of interest from the digital images;
obtaining at least one image of the at least one selected object of interest at a plurality of different wavelengths to form a set of multi-wavelength images;
analyzing the set of multi-wavelength images in order to characterize the at least one selected object.
12. The automated imaging process of claim 11, wherein the at least one object of interest comprises an object of relatively high optical density relative to other objects in the biological sample.
13. The automated imaging process of claim 11, wherein the digital images are obtained from at least one wavelength in the range from ultraviolet to infrared.
14. The automated imaging process of claim 13, wherein the digital images are obtained from at least one wavelength of less than about 670 nm.
15. The automated imaging process of claim 11, wherein the plurality of different wavelengths are at uniform increments.
16. The automated imaging process of claim 11, wherein the at least one object of interest comprise cells.
17. The automated imaging process of claim 16, wherein the process is used to identify a nucleus.
18. The automated imaging process of claim 17, wherein the process is used to identify the density of the nucleus.
19. The automated imaging process of claim 11, wherein the characterization of the selected object includes detection of a marker.
20. The automated imaging process of claim 11, wherein the process is used to determine a normal specimen.
21. The automated imaging process of claim 11, wherein the process is used to identify an infection or other disease.
22. The automated imaging process of claim 11, wherein the characterization of the selected object comprises detection of a spectral signature of an abnormal or infected cell.
US12/480,452 2005-05-02 2009-06-08 Automated image analysis Abandoned US20090245612A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/480,452 US20090245612A1 (en) 2005-05-02 2009-06-08 Automated image analysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/120,437 US7587078B2 (en) 2005-05-02 2005-05-02 Automated image analysis
US12/480,452 US20090245612A1 (en) 2005-05-02 2009-06-08 Automated image analysis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/120,437 Continuation US7587078B2 (en) 2005-05-02 2005-05-02 Automated image analysis

Publications (1)

Publication Number Publication Date
US20090245612A1 true US20090245612A1 (en) 2009-10-01

Family

ID=36710368

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/120,437 Active 2028-07-09 US7587078B2 (en) 2005-05-02 2005-05-02 Automated image analysis
US12/480,452 Abandoned US20090245612A1 (en) 2005-05-02 2009-06-08 Automated image analysis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/120,437 Active 2028-07-09 US7587078B2 (en) 2005-05-02 2005-05-02 Automated image analysis

Country Status (12)

Country Link
US (2) US7587078B2 (en)
EP (1) EP1877979A1 (en)
JP (1) JP2008541048A (en)
KR (1) KR20080007447A (en)
CN (1) CN101167101A (en)
AU (1) AU2006242644A1 (en)
BR (1) BRPI0611381A2 (en)
CA (1) CA2603801A1 (en)
IL (1) IL187123A0 (en)
MX (1) MX2007013581A (en)
TW (1) TW200709799A (en)
WO (1) WO2006118888A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015494A1 (en) * 2009-07-15 2011-01-20 Microscopes International, Llc Home healthcare management system and hardware
CN102519861A (en) * 2011-12-09 2012-06-27 南昌百特生物高新技术股份有限公司 Blood cell form multi-mode image screening method
US20130071002A1 (en) * 2011-09-15 2013-03-21 Takeshi Otsuka System and method for support of medical diagnosis
US20130279788A1 (en) * 2011-04-15 2013-10-24 Constitution Medical, Inc Measuring Volume and Constituents of Cells
US9558551B2 (en) 2012-11-27 2017-01-31 Panasonic Intellectual Property Management Co., Ltd. Image measurement apparatus and image measurement method for determining a proportion of positive cell nuclei among cell nuclei included in a pathologic examination specimen
US9710694B2 (en) 2007-09-21 2017-07-18 Leica Biosystems Imaging, Inc. Image quality for diagnostic resolution digital slide images

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7860727B2 (en) 2003-07-17 2010-12-28 Ventana Medical Systems, Inc. Laboratory instrumentation information management and control network
US8719053B2 (en) 2003-07-17 2014-05-06 Ventana Medical Systems, Inc. Laboratory instrumentation information management and control network
US7587078B2 (en) * 2005-05-02 2009-09-08 Cytyc Corporation Automated image analysis
WO2008079745A2 (en) * 2006-12-19 2008-07-03 Cytyc Corporation Systems and methods for processing an image of a biological specimen
GB2451076A (en) * 2007-07-16 2009-01-21 Illinois Tool Works Inspection apparatus and method using penetrating radiation
US8326014B2 (en) * 2007-09-28 2012-12-04 Cytyc Corporation Methods and systems for processing biological specimens utilizing multiple wavelengths
US9602777B2 (en) 2008-04-25 2017-03-21 Roche Diagnostics Hematology, Inc. Systems and methods for analyzing body fluids
JP2012515931A (en) * 2008-04-25 2012-07-12 ウィンケルマン、ジェイムズ System and method for determining total blood count and white blood cell percentage
GB2464747B (en) * 2008-10-10 2013-05-15 Hai Kang Life Corp Ltd Method for detection of analyte in microarray of samples and apparatus for performing such method
JP5601098B2 (en) * 2010-09-03 2014-10-08 ソニー株式会社 Fluorescence intensity correction method and fluorescence intensity calculation apparatus
CN102096914B (en) * 2011-01-26 2012-10-10 中国科学院自动化研究所 Method for eliminating interference of autologous florescence from biological fluorescence image
TWI708052B (en) * 2011-08-29 2020-10-21 美商安美基公司 Methods and apparati for nondestructive detection of undissolved particles in a fluid
US9020192B2 (en) 2012-04-11 2015-04-28 Access Business Group International Llc Human submental profile measurement
CN103413281B (en) * 2013-08-28 2016-03-30 西安电子科技大学 The method of the removal background fluorescence interference in the imaging of a kind of biological living fluorescence excitation
EP3016116A1 (en) 2014-11-03 2016-05-04 Roche Diagniostics GmbH Printed circuit board arrangement, coil for a laboratory sample distribution system, laboratory sample distribution system and laboratory automation system
WO2017057970A1 (en) * 2015-09-30 2017-04-06 주식회사 싸이토젠 Optical cell identification method
EP3529591B1 (en) 2016-10-20 2021-08-04 Optina Diagnostics, Inc. Method and system for detecting an anomaly within a biological tissue
KR102643765B1 (en) 2017-03-09 2024-03-05 홀로직, 인크. Systems and methods for automated preparation of biological specimens
US11067526B2 (en) 2017-08-17 2021-07-20 Abbott Point Of Care Inc. Devices, systems, and methods for performing optical and electrochemical assays
KR101926117B1 (en) * 2017-08-18 2018-12-06 주식회사 싸이토젠 A method for screening prostate cancer subjects based on androgen receptor variant
US10586336B2 (en) 2018-05-18 2020-03-10 Hong Kong Applied Science and Technology Research Institute Company Limited Image pre-processing for accelerating cytological image classification by fully convolutional neural networks
US11508168B2 (en) * 2018-10-15 2022-11-22 Upmc Systems and methods for specimen interpretation
CN115903205A (en) 2018-11-02 2023-04-04 豪洛捷公司 System for viewing entire sample images
TWI691936B (en) * 2019-09-02 2020-04-21 臺中榮民總醫院 Method for detecting, classifying and quantifying multiple targets in medical images
TWI817063B (en) 2019-11-25 2023-10-01 美商好樂杰公司 Digital imaging system and method
US11755845B2 (en) 2021-06-18 2023-09-12 International Business Machines Corporation Automated process for generating natural language descriptions of raster-based weather visualizations for output in written and audible form
TW202349336A (en) 2022-02-28 2023-12-16 美商好樂杰公司 Digital imaging system and method

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191940A (en) * 1978-01-09 1980-03-04 Environmental Research Institute Of Michigan Method and apparatus for analyzing microscopic specimens and the like
US4845552A (en) * 1987-08-20 1989-07-04 Bruno Jaggi Quantitative light microscope using a solid state detector in the primary image plane
US4998284A (en) * 1987-11-17 1991-03-05 Cell Analysis Systems, Inc. Dual color camera microscope and methodology for cell staining and analysis
US5016173A (en) * 1989-04-13 1991-05-14 Vanguard Imaging Ltd. Apparatus and method for monitoring visually accessible surfaces of the body
US5134662A (en) * 1985-11-04 1992-07-28 Cell Analysis Systems, Inc. Dual color camera microscope and methodology for cell staining and analysis
US5202931A (en) * 1987-10-06 1993-04-13 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear protein
US5485530A (en) * 1991-01-24 1996-01-16 Joseph R. Lakowicz Method and apparatus for multi-dimensional phase fluorescence lifetime imaging
US5548661A (en) * 1991-07-12 1996-08-20 Price; Jeffrey H. Operator independent image cytometer
US5764792A (en) * 1996-01-19 1998-06-09 Oncor, Inc. Method and apparatus for processing images
US6208749B1 (en) * 1997-02-28 2001-03-27 Electro-Optical Sciences, Inc. Systems and methods for the multispectral imaging and characterization of skin tissue
US20020081014A1 (en) * 1997-05-14 2002-06-27 Applied Imaging Corporation Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
US6438261B1 (en) * 1998-09-03 2002-08-20 Green Vision Systems Ltd. Method of in-situ focus-fusion multi-layer spectral imaging and analysis of particulate samples
US20030048933A1 (en) * 2001-08-08 2003-03-13 Brown Carl S. Time-delay integration imaging of biological specimen
US20040245350A1 (en) * 2003-06-03 2004-12-09 Haishan Zeng Methods and apparatus for fluorescence imaging using multiple excitation-emission pairs and simultaneous multi-channel image detection
US7587078B2 (en) * 2005-05-02 2009-09-08 Cytyc Corporation Automated image analysis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008185A (en) 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
US5995645A (en) * 1993-08-18 1999-11-30 Applied Spectral Imaging Ltd. Method of cancer cell detection
EP0839362A1 (en) * 1995-07-19 1998-05-06 Morphometrix Technologies Inc. Multi-spectral segmentation for image analysis
JP2003513268A (en) * 1999-10-29 2003-04-08 サイティック コーポレイション Cytological imaging system and method
JP2004286666A (en) * 2003-03-24 2004-10-14 Olympus Corp Pathological diagnosis support apparatus and pathological diagnosis support program
US8185317B2 (en) * 2003-06-12 2012-05-22 Cytyc Corporation Method and system of determining the stain quality of slides using scatter plot distribution

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191940A (en) * 1978-01-09 1980-03-04 Environmental Research Institute Of Michigan Method and apparatus for analyzing microscopic specimens and the like
US5134662A (en) * 1985-11-04 1992-07-28 Cell Analysis Systems, Inc. Dual color camera microscope and methodology for cell staining and analysis
US4845552A (en) * 1987-08-20 1989-07-04 Bruno Jaggi Quantitative light microscope using a solid state detector in the primary image plane
US5202931A (en) * 1987-10-06 1993-04-13 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear protein
US4998284A (en) * 1987-11-17 1991-03-05 Cell Analysis Systems, Inc. Dual color camera microscope and methodology for cell staining and analysis
US5016173A (en) * 1989-04-13 1991-05-14 Vanguard Imaging Ltd. Apparatus and method for monitoring visually accessible surfaces of the body
US5485530A (en) * 1991-01-24 1996-01-16 Joseph R. Lakowicz Method and apparatus for multi-dimensional phase fluorescence lifetime imaging
US5548661A (en) * 1991-07-12 1996-08-20 Price; Jeffrey H. Operator independent image cytometer
US5764792A (en) * 1996-01-19 1998-06-09 Oncor, Inc. Method and apparatus for processing images
US6208749B1 (en) * 1997-02-28 2001-03-27 Electro-Optical Sciences, Inc. Systems and methods for the multispectral imaging and characterization of skin tissue
US20020081014A1 (en) * 1997-05-14 2002-06-27 Applied Imaging Corporation Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
US6438261B1 (en) * 1998-09-03 2002-08-20 Green Vision Systems Ltd. Method of in-situ focus-fusion multi-layer spectral imaging and analysis of particulate samples
US20030048933A1 (en) * 2001-08-08 2003-03-13 Brown Carl S. Time-delay integration imaging of biological specimen
US20040245350A1 (en) * 2003-06-03 2004-12-09 Haishan Zeng Methods and apparatus for fluorescence imaging using multiple excitation-emission pairs and simultaneous multi-channel image detection
US7587078B2 (en) * 2005-05-02 2009-09-08 Cytyc Corporation Automated image analysis

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9710694B2 (en) 2007-09-21 2017-07-18 Leica Biosystems Imaging, Inc. Image quality for diagnostic resolution digital slide images
US20110015494A1 (en) * 2009-07-15 2011-01-20 Microscopes International, Llc Home healthcare management system and hardware
US8891851B2 (en) * 2009-07-15 2014-11-18 Glenn F. Spaulding Home healthcare management system and hardware
US20130279788A1 (en) * 2011-04-15 2013-10-24 Constitution Medical, Inc Measuring Volume and Constituents of Cells
US8922761B2 (en) * 2011-04-15 2014-12-30 Roche Diagnostics Hematology, Inc. Measuring volume and constituents of cells
US9588033B2 (en) 2011-04-15 2017-03-07 Roche Diagnostics Hematology, Inc. Measuring volume and constituents of cells
US10281382B2 (en) 2011-04-15 2019-05-07 Roche Diagnostics Hematology, Inc. Measuring volume and constituents of cells
US20130071002A1 (en) * 2011-09-15 2013-03-21 Takeshi Otsuka System and method for support of medical diagnosis
US8977017B2 (en) * 2011-09-15 2015-03-10 The General Hospital Corporation System and method for support of medical diagnosis
CN102519861A (en) * 2011-12-09 2012-06-27 南昌百特生物高新技术股份有限公司 Blood cell form multi-mode image screening method
US9558551B2 (en) 2012-11-27 2017-01-31 Panasonic Intellectual Property Management Co., Ltd. Image measurement apparatus and image measurement method for determining a proportion of positive cell nuclei among cell nuclei included in a pathologic examination specimen

Also Published As

Publication number Publication date
BRPI0611381A2 (en) 2010-08-31
AU2006242644A1 (en) 2006-11-09
TW200709799A (en) 2007-03-16
WO2006118888A1 (en) 2006-11-09
JP2008541048A (en) 2008-11-20
US20060245630A1 (en) 2006-11-02
CA2603801A1 (en) 2006-11-09
KR20080007447A (en) 2008-01-21
IL187123A0 (en) 2008-02-09
MX2007013581A (en) 2008-01-24
CN101167101A (en) 2008-04-23
US7587078B2 (en) 2009-09-08
EP1877979A1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
US7587078B2 (en) Automated image analysis
DK2973397T3 (en) Tissue-object-based machine learning system for automated assessment of digital whole-slide glass
EP1470411B1 (en) Method for quantitative video-microscopy and associated system and computer software program product
US6246785B1 (en) Automated, microscope-assisted examination process of tissue or bodily fluid samples
JP5469070B2 (en) Method and system using multiple wavelengths for processing biological specimens
US20060127880A1 (en) Computerized image capture of structures of interest within a tissue sample
EP1680757A1 (en) Automated microspcope slide tissue sample mapping and image acquisition
WO2003105675A2 (en) Computerized image capture of structures of interest within a tissue sample
JPH09509487A (en) Cell sample automatic classification device and method
CN114782372A (en) DNA fluorescence in situ hybridization BCR/ABL fusion state detection method and detection system
US7257243B2 (en) Method for analyzing a biological sample
Joseph Hyperspectral optical imaging for detection, diagnosis and staging of cancer
Wang et al. Fluorescence in situ hybridization (FISH) signal analysis using automated generated projection images
Wu et al. Image capture, analysis and quantification
Begelman et al. Automatic screening of bladder cells for cancer diagnosis
AU2012244307A1 (en) Methods and systems for processing biological specimens utilizing multiple wavelengths
Meyer-Ebrecht et al. Diagnostic Cytometry

Legal Events

Date Code Title Description
AS Assignment

Owner name: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL

Free format text: TWELFTH SUPPLEMENT TO PATENT SECURITY AGREEMENT;ASSIGNOR:CYTYC CORPORATION;REEL/FRAME:023012/0568

Effective date: 20090720

AS Assignment

Owner name: BIOLUCENT, LLC, CALIFORNIA

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: CYTYC SURGICAL PRODUCTS III, INC., MASSACHUSETTS

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: HOLOGIC, INC., MASSACHUSETTS

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: DIRECT RADIOGRAPHY CORP., DELAWARE

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP, MASSA

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: CYTYC CORPORATION, MASSACHUSETTS

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: R2 TECHNOLOGY, INC., CALIFORNIA

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: SUROS SURGICAL SYSTEMS, INC., INDIANA

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP, MA

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: CYTYC PRENATAL PRODUCTS CORP., MASSACHUSETTS

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

Owner name: THIRD WAVE TECHNOLOGIES, INC., WISCONSIN

Free format text: TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS;ASSIGNOR:GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT;REEL/FRAME:024892/0001

Effective date: 20100819

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION